Cargando…
p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya
BACKGROUND: The identification of suited early detection tests is one among the multiple requirements to reduce cervical cancer incidence in developing countries. METHODS: We evaluated p16(INK4a)/Ki-67 dual-stain cytology in a screening population in Thika district, Kenya and compared it to high-ris...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531480/ https://www.ncbi.nlm.nih.gov/pubmed/26265934 http://dx.doi.org/10.1186/s13027-015-0020-2 |
_version_ | 1782385045115240448 |
---|---|
author | Ngugi, Caroline Wangari Schmidt, Dietmar Wanyoro, Karanja Boga, Hamadi Wanzala, Peter Muigai, Anne Mbithi, John von Knebel Doeberitz, Magnus Reuschenbach, Miriam |
author_facet | Ngugi, Caroline Wangari Schmidt, Dietmar Wanyoro, Karanja Boga, Hamadi Wanzala, Peter Muigai, Anne Mbithi, John von Knebel Doeberitz, Magnus Reuschenbach, Miriam |
author_sort | Ngugi, Caroline Wangari |
collection | PubMed |
description | BACKGROUND: The identification of suited early detection tests is one among the multiple requirements to reduce cervical cancer incidence in developing countries. METHODS: We evaluated p16(INK4a)/Ki-67 dual-stain cytology in a screening population in Thika district, Kenya and compared it to high-risk human papillomavirus (HR-HPV) DNA testing and visual inspection by acetic acid (VIA) and Lugol’s iodine (VILI). RESULTS: Valid results for all tests could be obtained in 477 women. 20.9 % (100/477) were tested positive for HR-HPV DNA, 3.1 % (15/477) had positive VIA/VILI and 8.2 % (39/477) positive p16(INK4a)/Ki-67 cytology. Of 22 women that showed up for colposcopy and biopsy, 6 women were diagnosed with CIN3 and two with CIN2. All women with CIN2/3 were negative in VIA/VILI screening and positive by HR-HPV DNA testing. But HPV was also positive in 91.7 % (11/12) of women with normal histology. p16(INK4a)/Ki-67 cytology was positive in all 6 women with CIN3, in one of the two CIN2 and in only 8.3 % (1/12) of women with normal histology. CONCLUSIONS: p16(INK4a)/Ki-67 cytology is an interesting test for further studies in developing countries, since our findings point to a lower fraction of false positive test results using p16(INK4a)/Ki-67 cytology compared to HPV DNA testing in a Kenyan screening population. VIA/VILI missed all histology-proven CIN2/3. |
format | Online Article Text |
id | pubmed-4531480 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45314802015-08-12 p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya Ngugi, Caroline Wangari Schmidt, Dietmar Wanyoro, Karanja Boga, Hamadi Wanzala, Peter Muigai, Anne Mbithi, John von Knebel Doeberitz, Magnus Reuschenbach, Miriam Infect Agent Cancer Research Article BACKGROUND: The identification of suited early detection tests is one among the multiple requirements to reduce cervical cancer incidence in developing countries. METHODS: We evaluated p16(INK4a)/Ki-67 dual-stain cytology in a screening population in Thika district, Kenya and compared it to high-risk human papillomavirus (HR-HPV) DNA testing and visual inspection by acetic acid (VIA) and Lugol’s iodine (VILI). RESULTS: Valid results for all tests could be obtained in 477 women. 20.9 % (100/477) were tested positive for HR-HPV DNA, 3.1 % (15/477) had positive VIA/VILI and 8.2 % (39/477) positive p16(INK4a)/Ki-67 cytology. Of 22 women that showed up for colposcopy and biopsy, 6 women were diagnosed with CIN3 and two with CIN2. All women with CIN2/3 were negative in VIA/VILI screening and positive by HR-HPV DNA testing. But HPV was also positive in 91.7 % (11/12) of women with normal histology. p16(INK4a)/Ki-67 cytology was positive in all 6 women with CIN3, in one of the two CIN2 and in only 8.3 % (1/12) of women with normal histology. CONCLUSIONS: p16(INK4a)/Ki-67 cytology is an interesting test for further studies in developing countries, since our findings point to a lower fraction of false positive test results using p16(INK4a)/Ki-67 cytology compared to HPV DNA testing in a Kenyan screening population. VIA/VILI missed all histology-proven CIN2/3. BioMed Central 2015-08-11 /pmc/articles/PMC4531480/ /pubmed/26265934 http://dx.doi.org/10.1186/s13027-015-0020-2 Text en © Ngugi et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Ngugi, Caroline Wangari Schmidt, Dietmar Wanyoro, Karanja Boga, Hamadi Wanzala, Peter Muigai, Anne Mbithi, John von Knebel Doeberitz, Magnus Reuschenbach, Miriam p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya |
title | p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya |
title_full | p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya |
title_fullStr | p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya |
title_full_unstemmed | p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya |
title_short | p16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya |
title_sort | p16(ink4a)/ki-67 dual stain cytology for cervical cancer screening in thika district, kenya |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531480/ https://www.ncbi.nlm.nih.gov/pubmed/26265934 http://dx.doi.org/10.1186/s13027-015-0020-2 |
work_keys_str_mv | AT ngugicarolinewangari p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya AT schmidtdietmar p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya AT wanyorokaranja p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya AT bogahamadi p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya AT wanzalapeter p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya AT muigaianne p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya AT mbithijohn p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya AT vonknebeldoeberitzmagnus p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya AT reuschenbachmiriam p16ink4aki67dualstaincytologyforcervicalcancerscreeninginthikadistrictkenya |